[MEINNTECH] Based on the development of original technology, our aim is to be an enterprise
- Name 관리자
- Date 2022-12-23
Based on the development of original technology, our aim is to be an enterprise
that thrives for the next 100 years
Q. Please introduce us to MEINNTECH.
Innovating the ecosystem of the domestic medical device industry by securing original technology
A. Since MEINNTECH’s founding in 2001, we have been manufacturing and selling an intravenous infusion controller set that can be operated with one hand (EZ Regular), the world’s first cylinder infusion pump (Anyfusion), and an automated preparation machine for anticancer (injection) medicine (Anyfusion ACPi V100). The “cylinder infusion pump” fundamentally blocks any possibility of the incorrect injection of medicine and its contamination by converting the linear motion of the syringe to a rotational motion. Along with Anyfusion, the technology of the automated preparation machine for anticancer medicine are the first of their kind to be commercialized. Both technologies are currently exported through 40 global networks including U.S., Japan, and Germany under our own brand. We are convinced that the only way to change the ecosystem of the domestic medical device industry is through developing original technology. In this regard, we will continue our efforts to advance technological innovation and develop a self-operated hemodialyzer and a portable blood infusion pump so that we can grow as a globally recognized company.
Q. Briefly tell us about the advantages of the ‘cylinder medicine infusion pump (Anyfusion) and its cartridge
Ensuring safety by combining the advantages of an infusion pump and a syringe pump
A. Our company’s Anyfusion product is a solution that combines the advantages of an infusion pump and a syringe pump. Anyfusion fundamentally blocks any possibility of the incorrect injection of medicine and its contamination by converting the linear motion of a syringe to a rotational motion. An infusion pump is less accurate but appropriate for a large volume. A syringe pump is accurate enough to be used for anticancer medicine and antibiotics but has the shortcoming of needing to be replaced every hour. Our product comes with an innovative smart monitoring system that makes it possible to monitor and manage the operation and infusion of a pump as well as patient information in real time from a hospital’s central control office. It also has screen-touch functionality, and any chance of under- or over-dosing is eliminated. The automated priming system enhances user convenience and minimizes the loss of medicine. The cylinder cartridge set can be used for 72 hours and alleviate the heavy workload caused by frequent cartridge replacements.
Q. Tell us about your plan to expand your business into overseas markets and its future directions or blueprint.
Entering into the US market in 2023 and growing as a global company
A. In a bid to grow as an influential manufacturing business in the global medical device industry, our company is working hard and negotiating with buyers on matters including business arrangements, business support, demonstrations at local hospitals, and licensing in each country. We are seeking to increase sales by establishing our brand power and settling in overseas markets. Next year, we plan to win FDA approval and enter the US market. MEINNTECH will strive to become a global leader and help patients experience quality medical services by developing innovative medical devices based on various application technologies that can prevent medical accidents.